NY-ESTÉE-LAUDER
12.7.2024 00:16:31 CEST | Business Wire | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announced that Tracey T. Travis, Executive Vice President and Chief Financial Officer, has decided to retire, effective June 30, 2025, after more than twelve years of exemplary leadership and service at the company. A successor for the CFO role has been identified and will be named in the coming weeks. Tracey will work closely with this person to ensure a smooth and successful transition.
“Tracey has been an invaluable business partner and a trusted advisor to me, our executives and Board of Directors, as well as a mentor and role model to many across our organization,” said Fabrizio Freda, President and Chief Executive Officer. “She has built and led a robust, integrated Global Finance & Strategy organization that has served as a valued business partner across the company and has helped to optimize delivery of our financial plans. Her financial acumen, discipline, and operational excellence have been essential to our company’s growth, and so many areas of our organization have her valuable imprint on them.”
Since joining The Estée Lauder Companies (ELC), Tracey has led the company’s Global Finance, Accounting, Tax, Treasury, Investor Relations, Information Technology, and Strategy and New Business Development organizations. Tracey has also co-led the company’s Global Value Council and served as a member of the Executive Leadership Team and the Investment Development Committee. Tracey has also been a respected and engaging leader in her extensive work with our global investor community.
Under her guidance, the company has enhanced its financial strength and flexibility, enabling us to further invest in our long-term growth drivers, such as innovation, digital transformation, emerging markets, talent development, and M&A strategy. Additionally, Tracey has played a pivotal role in leading and advancing the financial profile of our global brand portfolio.
Over the last twelve years, Tracey built a robust, integrated Global Finance & Strategy (F&S) organization at ELC that serves as a valued business partner across the company, with a particular focus on cultivating talent across the organization to bring new perspectives to the finance function. Under her leadership, F&S has provided financial guidance throughout the enterprise while maximizing business and transformational opportunities, optimizing the capital structure, and supporting brand growth strategies and cash management. Tracey leaves the F&S function a transformed organization.
Together with ELC’s senior leadership, Tracey has deeply embedded the company’s corporate strategy throughout the organization, solidifying core planning processes with an emphasis on executional excellence. Working alongside senior leadership, Tracey and her team have implemented and driven a progressive end-to-end M&A strategy and value-driven empowerment and integration, including many important strategic acquisitions and investments such as DECIEM and TOM FORD. Tracey has also led the New Incubation Ventures (NIV) team to enable the sourcing, building, and growth of the brands and business models of tomorrow.
Tracey has helped further improve and elevate the company’s Information Technology function, strengthening its competitive edge through investments in areas such as digital tech centers around the world, embodying ELC’s global approach to technology management and innovation and enhancing the diversity of its capabilities. Tracey also served as an instrumental leader in establishing the company’s shared services capability to support the business and its growth.
Tracey played a critical role in strengthening talent development and engagement by developing and growing ELC’s Finance & Strategy Leadership Development Program (FASLEAP), and guiding the function’s approach to identifying, training, and placing top talent. Tracey has also been a committed Global Executive Sponsor of the Women’s Leadership Network (WLN) employee resource group (ERG), where she helped further a culture of recognizing women as pioneers in the beauty industry and highlighting their creativity and ingenuity in shaping trends and redefining standards. She has been a passionate advocate for the company’s efforts across philanthropy, citizenship and sustainability, and inclusion, diversity and equity, including by championing initiatives to advance racial equity and representation within the company and the beauty industry.
“An inspiring and visionary leader, Tracey has been deeply committed to exemplifying our values throughout her years of dedicated service to our company,” said William P. Lauder, Executive Chairman. “Tracey has had a remarkable impact on driving our business forward by leading our portfolio strategy, but also by developing our talent, cultivating a culture of inclusion and continued learning, and advancing initiatives to foster a more diverse and equitable workplace and marketplace.”
Tracey has been honored with numerous industry awards and accolades throughout her distinguished career. She received a Best CFO award by Institutional Investor magazine, was recognized as one of the “Top 100 African Americans in Corporate America,” as well as “The Most Powerful Women in Corporate America” by Black Enterprise magazine. In 2019, she was honored with an Achiever Award by Cosmetic Executive Women. Tracey currently serves as a director on the Board of Accenture PLC and the Board of Meta Platforms Inc. (formerly, Facebook).
ABOUT THE ESTÉE LAUDER COMPANIES
The Estée Lauder Companies Inc. is one of the world’s leading manufacturers, marketers, and sellers of quality skin care, makeup, fragrance, and hair care products, and is a steward of luxury and prestige brands globally. The company’s products are sold in approximately 150 countries and territories under brand names including: Estée Lauder, Aramis, Clinique, Lab Series, Origins, M·A·C, La Mer, Bobbi Brown Cosmetics, Aveda, Jo Malone London, Bumble and bumble, Darphin Paris, TOM FORD, Smashbox, AERIN Beauty, Le Labo, Editions de Parfums Frédéric Malle, GLAMGLOW, KILIAN PARIS, Too Faced, Dr.Jart+, and the DECIEM family of brands, including The Ordinary and NIOD.
For more information, visit www.elcompanies.com.
ELC-C
ELC-L
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240711879987/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Murata Launches Ultra-Low Power AMR Sensors to Boost Battery Life in Healthcare and Wearables Devices27.4.2026 04:00:00 CEST | Press release
Murata Manufacturing Co., Ltd. (TOKYO: 6981) (ISIN: JP3914400001) has commenced mass production of its MRMS166R and MRMS168R anisotropic magnetoresistance (AMR) sensors for healthcare, wearable, and IoT devices. The MRMS166R is the first AMR sensor to combine an average current consumption of 20 nA with operation from a 1.2 V supply, enabling extended battery life in coin cell-powered systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260413296947/en/ [Murata Manufacturing Co., Ltd.] AMR sensor The devices are solid-state magnetic sensors used for switching applications. They detect the presence or absence of a magnetic field and generate an output signal that system logic uses to control functions such as transitions between active and sleep modes. This enables contactless switching without mechanical components, improving reliability, and supporting sealed, miniaturized designs. Automatic switching between active and
Sun Pharma signs Definitive Agreement to Acquire Organon27.4.2026 01:51:00 CEST | Press release
Organon stockholders to receive US$ 14.00 per share in cashThe deal values Organon at EV of US$ 11.75 billionCombined Business leverages complementary portfolios and global scale for sustained long‑term value creation Sun Pharmaceutical Industries Limited(Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, “Sun Pharma”) and Organon & Co. (NYSE: OGN) (“Organon”) today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.75 billion. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260426881370/en/ Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of the United States and Canada, in 2021. Organon has a legacy of deep trust and strong brand equit
Andersen Global udvider sin tilstedeværelse i Afrika med lanceringen af medlemsfirma i Cameroun26.4.2026 20:56:00 CEST | Pressemeddelelse
Andersen Global træder ind på det camerounske marked, idet Phoenix Advisory bliver medlemsfirma og overgår til Andersen-brandet. Andersen in Cameroun er et specialiseret rådgivningsfirma, der leverer strategiske, erhvervsmæssige, finansielle og operationelle rådgivningsydelser til organisationer i forskellige vækstfaser. Firmaet er grundlagt af fagfolk med erfaring fra store internationale organisationer og kombinerer et stærkt lokalt og centralafrikansk funderet kendskab til forretningsmæssige, juridiske og skattemæssige regler med en skræddersyet tilgang, der har til formål at skabe konkrete og målbare resultater for klienterne. "Overgangen til Andersen-brandet afspejler vores engagement i at vokse sammen med vores kunder og imødekomme stadig mere komplekse behov," udtalte administrerende partner Albert Désiré Zang. "Vi tror på, at langsigtet succes skabes gennem tillid, kvalitet og vedvarende support. At blive et medlemsfirma styrker vores evne til at levere gennemtænkte, bæredygtig
PMCOrganometallix Announces Price Increase on All Products24.4.2026 22:55:00 CEST | Press release
Due to significant changes in market conditions, PMC Organometallix, Inc. announces that effective May 1, 2026, or as contracts permit, prices across all product lines globally will increase by 10-25%. This adjustment is driven by sustained cost pressures from key inputs including rising raw material costs and escalating freight and logistics expenses. While the company has been absorbing these increases, the current economic environment brought on by the geopolitical crisis of the Iran conflict requires this adjustment to continue providing the high-quality, consistent materials and supply reliability that customers expect. PMC Organometallix will implement these changes in a transparent, collaborative manner and values your partnership while navigating these economic challenges. Customers with questions or to discuss a specific situation should contact their account representative. About PMC Group PMC Group is a growth-oriented, diversified, global chemicals and plastics company deli
Frankfurt Higher Regional Court upholds BESREMi® arbitral award in favor of AOP Health24.4.2026 18:52:00 CEST | Press release
Today, the Higher Regional Court of Frankfurt upheld the February 20251 partial final ICC arbitral award in favor of AOP Orphan Pharmaceuticals GmbH (“AOP Health”) in its dispute with PharmaEssentia Corp. (“PharmaEssentia”). The ruling confirms the award which found the Taiwanese company to be liable for certain damages. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260424005227/en/ Portrait Dr. Rudolf Widmann, Founder AOP Health Credit: AOP Health/Daniel Ospelt Dr. Rudolf Widmann, one of the two founders of AOP Health, explains: “We very much welcome the Frankfurt Higher Regional Court’s decision that confirms our position. In the interest of our patients, we are dedicated to maintaining stable and sustainable access to BESREMi® and to responsibly navigating future challenges.” The Product in Dispute The conflict centers around BESREMi® (ropeginterferon alfa-2b), a product launched in 2019 and developed by AOP Health into
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
